08:18 AM EDT, 10/23/2026 (MT Newswires) -- The UK Medicines and Healthcare products Regulatory Agency approved Johnson & Johnson (JNJ.F) unit Janssen-Cilag's icotrokinra hydrochloride tablet to treat severe plaque psoriasis. The approval was based on four late-stage clinical trials, in which the drug showed efficacy in treating moderate to severe plaque psoriasis after 16 weeks, compared with placebo, according to a Friday release. Icotrokinra hydrochloride is indicated for patients aged 12 and above with moderate to severe plaque psoriasis, who weigh at least 40 kilograms and are candidates for systemic therapy. Plaque psoriasis is an inflammatory condition causing scaly, itchy, and painful skin on the scalp, genitals, hands and feet, or nails.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.